How does Homeopathic Formulations work for Female Libido Enhancement?

creator of word

Mahankal (Shiv Linga) Ujjain India

How does Homeopathic Formulations work for Female Libido Enhancement?

We all well aware when  first time Viagra broke onto the market over a decade ago, women from around the world have been jealous in a way and have been constantly searching for a female libido enhancer that can prove to be just as beneficial. Even the way male sexual health products are marketed give off the feeling that men get to have all the fun when it comes to the bedroom.

But maybe it doesn’t have to be that way. What if there was a female libido enhancer that actually worked to increase  female sexual desire and improve sex for women all around the world? Could there really be such a thing as Viagra for women or are all supposed female enhancement products a farce?

In order to understand how female libido enhancement works, we first need to understand why so many women experience a loss of sex drive. While many assume problems with low libido arise from hormonal imbalances, lack of desire often is a direct result of psychological issues and emotions such as stress, depression, boredom, or even lifestyle choices that lead to lack of exercise or poor diet.

Therefore these  all of the issues that a top of the line female enhancement product should target, and that is why Homeopathic Formulations  has become so popular over the years. Homeopathic Formulations   is an all natural herbal supplement that combines a number of potent herbal   ingredients that elevate  mood, increase desire, and really allow you to leave your worries behind and focus on full and satisfying pleasure. Whether you avoid sex because you simply do not have the time, are bored with the results, or cannot get yourself   in the mood, this female enhancement  Homeopathic Formulations is designed for you.

Unfortunately the little blue pill known as Viagra just does not have the same effect on women as it does on men. So sneaking a few pills from  your husband’s bedside drawer isn’t going to do the trick. That is because you need a product that is tailored specifically towards your needs as a woman, and not one that is aimed at warding off and treating erectile dysfunction.

Don’t you find it a bit odd that men’s sexual health products seem to take over the market even though it is far more common for women to be less sexually satisfied then men? That is precisely why the   Homeopathic  Formulations prepared.

What’s New in Foot and Ankle Surgery: Level I and II Studies


Every month, JBJS publishes a Specialty Update—a review of the most pertinent and impactful studies published in the orthopaedic literature during the previous year in 13 subspecialties. Here is a summary of selected findings from Level I and II studies cited in the May 20, 2015 Specialty Update on foot and ankle surgery:

Talar and Calcaneal Fractures

Ankle Instability

  • A prospective randomized…

View original post 282 more words

Now eye disorder namely Retinitis Pigmentosa can be treated in India

At Indore (India) treatment of Retinitis Pigmentosa an eyes disease is available. A new treatment (operation) technique namely Technique of  Omentopexy can  treat this disease. Recently Dr Denial a renowned surgeon learned this technique from Dr A.K. Agarwal of Indore (India). Dr A K Agarwal and eye surgeon Dr P S Hardia demonstrated this technique before Dr Daniel by successfully performing operation of a Patient for 6 Hours. Dr Danial was surprised to see that and praised Dr Agarwal performance.  Now he would try to seek patent in the name of Dr Agarwal.

Dr Danial told that in world among 10 lakhs people  there are 200 people  suffering from this diseases (Retinitis Pigmentosa) a eye hereditary disease, in this the people by the reaching the age of 20-25 patients loses his eye sight. There are more people suffering in USA than other countries. There is no treatment there. Now there is new hope of successful treatment of sufferers. There the treatment cost would be about 18-20 lakhs Rupees( 30000 USD). That is nothing looking to the seriousness of the disease.

Since 50 years Doctors of 50 countries were trying and doing research for treatment of this disease.

In this technique Omentus of nerves available at stomach side used and this is spread to retinus artery. This creates blood circulation in retina. And vision is restored.(news in  Danik

New advances in Arthroscopy surgery the use of Disposable Arthroscope

The biggest changes in orthopedic surgery   is use of disposable arthroscope thereby prevention of infection to a great extent.

Grady L. Jeter, MD, the founder of the Arthroscopy & Sports Medicine Clinic in San Jose, Calif., shares his thoughts on some of the most significant changes in the field of orthopedic surgery.

He told “I have seen many changes in orthopedic surgery since I began practicing in 1969, but the biggest change for me has been the development of arthroscopic surgery and its continuous advancements. In particular, the addition of a camera enabled the use of the scope by a large majority of orthopedic surgeons—rather than confining it to the ambidextrously gifted few”

More recently, the introduction of a disposable arthroscope eliminates infection risks and provides first-time quality for every procedure. Over time, arthroscopes get damaged and degraded in optical quality due to frequent use, handling, and reprocessing. A single-use arthroscope, like the nuvisTM from Integrated Endoscopy, provides surgeons with a brand new scope every time, eliminates the burden of reprocessing the scopes, and assures patients of a sterile scope free of the potential for infection transmission.

These advancements allow the surgeons  to utilize the most technically advanced surgical techniques, while providing the safest, most reliable and least intrusive methods possible to  their patients.

16 spine devices received FDA clearance in March 2015

There is news in social media that  16 spine devices received FDA  clearance in March  2015      

 The Food and Drug Administration  granted 16 spine-related devices clearances in March.2015

1. MAGEC Spinal Bracing and Distraction System from Ellipse Technologies.

2. NuVasive CoRoent System from NuVasive.

3. Biomet Spine Fusion System from Biomet Spine.

4. PASS LP Spinal System from Medicrea.

5. Xenco Medical Lumbar Interbody System from Xenco Medical.

6. LnK Anterior Cervical Plate System from L&K Biomed.

7. Affix IIS Spinous Process Plate System from NuVasive.

 8. AccuLIF TL and PL Cage from Stryker.

 9. inVizia Anterior Cervical Plate System from Zimmer Spine.

10. NuVasive NVM5 System from NuVasive.

11. Leva Spacer System from Spine Wave.

12. Range/Denali/Mesa Spinal System from K2M.

13. Tarsa-Link Wedge Fixation System from Life Spine.

14. Nautilus Spinal System from Life Spine. 15. LITe Plate System from Stryker.

16. Integra Laminoplasty System from SeaSpine.

It is to mention here that in spine and other orthopedics surgeries FDA approved devices are used word wide.

US Docs involved in $7M fraud scheme involving homeless patients of New York city.

There is recently a news in New York Times that Twenty-three people, including   nine physicians, have  been indicted  for their involvement in a $7 million  healthcare  fraud s cheme  that  involved  rounding up homeless people in New York City and subjecting them  to unnecessary medical  testing in exchange for shoes.

Eric Vainer and his mother oversaw  the operation. Mr. Vainer sent recruiters to homeless shelters, soup kitchens and welfare offices to pick up homeless people with valid Medicaid cards and take them  to medical clinics that were involved  in the scheme.  Prosecutors said there were multiple ways Mr. Vainer made money through   the scheme, as he owns medical clinics and  had  financial arrangements with physicians, according to the new in  New York Times.

“We can use the same patients like guinea pigs for  anything  we want,” Mr. Vainer was recorded  saying in a government wiretap, according to the report.m

Kenneth P. Thompson, the Brooklyn district attorney, told The New York Times the investigation began after a woman was recruited to one of the clinics involved in the scheme and was told she would  have to take a knee brace to get a pair of sneakers.

Physicians involved in the scheme allegedly billed Medicaid   for procedures that were never done and would  bill for much longer patient visits than had actually occurred, according to the report.

So it is highly unethical practice doing the docs and this is a malpractice and giving bad signals to others.

Now Patients own stem and regenerative cells from adipose tissue can heal Their osteoarthritis

The Regenerative Medicine Division of Cellthera, Ltd. developed a unique treatment strategy for degenerative osteoarthritis (commonly called also “arthrosis” or “joint arthritis”) and related orthopedic diseases/conditions. We are able to use your own (autologous) stem and regenerative cells that are located in so called stromal vascular fraction (SVF) of your fat (adipose tissue). Adipose tissue from the abdomen is easily accessible and can be obtained in local anesthesia by standard tumescent liposuction. SVF cells are isolated and getting activated in a specialized extraclean lab that is certified by the State Institute for Drug Control of the Czech Republic according to the highest European standards for tissue and cell processing. Freshly isolated SVF cells are injected immediately to the connective tissue of target joint(s) suffering from osteoarthritis. We can treat several joints at one procedure. The patient spend only 3-4 hours at the Cellthera Clinic. Recovery after the procedure to normal physical activity is very fast within days to weeks. Patients can enjoy much better quality of life including relief from joint pain and improved joint mobility after this cell therapy procedure.

What  Patient need to do before coming to Cellthera Clinic:

  1. see if you qualify for stem cell therapy at Cellthera Clinic – Inclusion/Exclusion Criteria are bellow;
  2. ask your physician or general practitioner for general medical examination before liposuction including evaluation of bleeding disorder or blood cloth disorder;
  3. prepare X-ray of target joints;
  4. send request for stem cell therapy to Cellthera Clinic.
  5. you can also ask your medical facilitator  for assistance with lodging and travel to and from Brno, Czech Republic.

Inclusion Criteria for stem cell therapy of orthopedic conditions:


  1. 18 years of age and older
  2. degenerative joint osteoarthritis of 1-4 large joints or up to 8 other joints including hip, knee, shoulder, elbow, wrist, hand, ankle, foot causing clinical symptoms such as joint pain, decreased joint mobility or significant functional disability verified by clinical examination and X-ray;
  3. osteochondropathy, osteochondrosis dissecans;
  4. tendinopathy, tendinitis;
  5. synovitis;
  6. no significant joint deformity;
  7. failure of conservative management.


Exclusion Criteria for stem cell therapy:


  1. active inflammatory or infectious disease;
  2. severe cardiac, pulmonary or other systemic disease;
  3. history of cancer and its treatment including chemotherapy and/or radiotherapy within the past 12 months;
  4. use of corticosteroid drugs within the past 4 weeks;
  5. health condition (including known allergy to local anesthetic drug) that does not allow to perform liposuction in local anesthesia;
  6. pregnancy or lactation;
  1. previous total joint arthroplasty of target joint.

Farydak (panobinostat) for the treatment of patients with multiple myeloma.

The U.S. Food and Drug Administration had approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.

Multiple myeloma is a form of blood cancer that arises from plasma cells, a type of white blood cell, found in bone marrow. According to the National Cancer Institute, approximately 21,700 Americans are diagnosed with multiple myeloma and 10,710 die from the disease annually.

Primarily affecting older adults, multiple myeloma causes plasma cells to rapidly multiply and crowd out other healthy blood cells from the bone marrow. When the bone marrow has too many plasma cells, the cells may move to other parts of the body, which can weaken the body’s immune system, lead to anemia and cause other bone and kidney problems.

Farydak works by inhibiting the activity of enzymes, known as histone deacetylases (HDACs). This process may slow the over-development of plasma cells in multiple myeloma patients or cause these dangerous cells to die.

Farydak is the first HDAC inhibitor approved to treat multiple myeloma. It is intended for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Farydak is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication.

“Farydak has a new mechanism of action that distinguishes it from prior drugs approved to treat multiple myeloma, making it a potentially attractive candidate agent for the treatment of multiple myeloma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Farydak’s approval is particularly important because it has been shown to slow the progression of multiple myeloma.”

In November 2014, the FDA’s Oncologic Drugs Advisory Committee advised the agency that, based on the data reviewed, the drug’s benefits did not outweigh its risks for patients with relapsed multiple myeloma. After the meeting, the company submitted additional information supporting Farydak’s use for a different indication: patients with multiple myeloma who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent.

The safety and efficacy of Farydak in combination with bortezomib and dexamethasone was demonstrated in 193 clinical trial participants with multiple myeloma who received at least two prior treatments that included bortezomib and an immunomodulatory agent. Participants were randomly assigned to receive a combination of Farydak, bortezomib and dexamethasone, or bortezomib and dexamethasone alone.

Study results showed participants receiving the Farydak combination saw a delay in their disease progression (progression-free survival) for about 10.6 months, compared to 5.8 months in participants treated with bortezomib and dexamethasone alone. Additionally, 59 percent of Farydak-treated participants saw their cancer shrink or disappear after treatment (response rate), versus 41 percent in those receiving bortezomib and dexamethasone.

Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Because of these risks, Farydak is being approved with a Risk Evaluation and Mitigation Strategy (REMS) consisting of a communication plan to inform health care professionals of these risks and how to minimize them.

The most common side effects of Farydak were diarrhea, tiredness, nausea, swelling in the arms or legs, decreased appetite, fever, vomiting and weakness. The most common laboratory abnormalities were low levels of phosphorus in the blood (hypophosphatemia), low potassium levels in the blood (hypokalemia), low levels of salt in the blood (hyponatremia), increased creatinine, low platelets (thrombocytopenia), low white blood cell counts (leukopenia) and low red blood cell counts (anemia). Healthcare professionals should also inform patients of the risk of bleeding in the gastrointestinal tract and the lungs, and liver damage (hepatotoxicity).

The FDA granted Farydak priority review and orphan product designation. Priority review provides for an expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over available therapy. Orphan product designation is given to drugs intended to treat rare diseases.

The FDA action was taken under the agency’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. The accelerated approval program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials. An improvement in survival or disease-related symptoms has not yet been established for Farydak. The company is now required to conduct confirmatory trials to verify and describe the clinical benefit of Farydak.

Farydak is marketed by East Hanover, New Jersey-based Novartis Pharmaceuticals.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


!5 points of Mr President Obama $3.99 trillion health care budget for American for 2016 fiscal begining Oct 1

It is  in news that President Obama had shared his $3.99 trillion budget proposal Monday for the 2016 fiscal year, which begins Oct. 1. Here are 15 of the budget’s key proposals related to healthcare.

1. The proposed budget allotment for HHS is up 4.3 percent for 2016, and the budget includes full funding for ongoing implementation of the Patient Protection and Affordable Care Act with no serious changes to its implementation. In fiscal 2016, HHS would receive authority over approximately $1.09 trillion, up from $1.04 trillion in fiscal 2015, according to the Wall Street Journal. Of that pool, $83.8 billion would be discretionary funding.

2. Despite the increase to the agency, the budget includes approximately $400 billion in reductions and reforms to Medicare, Medicaid and other HHS programs over the next decade.

3. The proposed long-term $400 haircut to Medicare spending breaks down in several ways, including smaller Medicare payments to teaching hospitals to better align with patient costs — a $1 billion reduction to graduate medical education payments in fiscal 2016, amounting to a $16.26 billion reduction over 10 years. The budget would also reduce inflation updates for post-acute providers that care for Medicare beneficiaries, reductions that would amount to $1.6 billion in fiscal 2016 and $102 billion over the next decade. Critical access hospitals face a payment reduction as well, from 101 percent of reasonable costs to ensure they remain viable to 100 percent. This would cost CAHs $110 million in 2016 and $1.73 billion over the next decade.

4. Beginning in 2019, the budget calls for increases to Medicare premiums for high-income beneficiaries and added charges for new enrollees. These new enrollee charges include a new copayment system for home healthcare services (saving Medicare $830 million over 10 years) and changes to the Part B deductible (saving $3.74 billion over 10 years). The budget would also collect $3.97 billion over 10 years through a surcharge on premiums for new beneficiaries who buy private insurance to supplement Medicare.

5. Despite the long-term reductions to Medicare and HHS programs, there are some proposed wins for healthcare providers. The budget would abolish the sequester’s automatic 2 percent cut in Medicare payments to providers, which were enacted by the Budget Control Act of 2011 to be carried out through 2021. The budget also proposes a repeal of Medicare’s sustainable growth rate reimbursement formula, a decisive move that has been avoided through short-term legislation since 2002. (The Brookings Institution estimates a permanent SGR repeal could cost $150 billion over 10 years.)

6. The budget reinforces the Obama administration’s goal of ensuring 30 percent of Medicare payments are made through alternative payment models by 2016 and 50 percent by 2018.

7. One of the biggest changes proposed in the budget is for the HHS secretary to have authority to negotiate prices for biologics and high-cost drugs in the Medicare Part D program and the authority to suspend coverage and payment for questionable Part D prescriptions. Currently, private insurers bargain on behalf of Medicare beneficiaries. The introduction of Sovaldi, a $1,000-a-pill hepatitis-C drug, and other high-price specialty drugs may have expedited this proposed change within the past year.

The budget also proposes to close the coverage gap for brand drugs in the Part D benefit by 2017, three years earlier than under current law, by increasing the discounts offered by the pharmaceutical industry. President Obama also proposed a program to reduce prescription drug abuse in Medicare and increased alignment of Medicare payments for drugs with Medicaid’s policies for low-income beneficiaries.

The aforementioned pharma-related proposals would save Medicare approximately $126 billion over 10 years.

8. The budget calls for a one-year extension of the PPACA policy that equalizes Medicaid reimbursement rates with Medicare reimbursement rates for primary care services.

9. The budget requests a four-year extension of the Children’s Health Insurance Program through 2019, as well as the program’s contingency fund. A state may qualify for contingency funds if it projects a funding shortfall and if its average monthly child enrollment exceeds a target number. This extension would be funded through an increase in tobacco taxes.

10. The budget would invest $810 million in 2016 and $2.1 billion from 2017 through 2020 in the National Health Services Corps to place and maintain 15,000 healthcare providers in the areas where they are most in demand.

11. The budget includes an increase of more than $550 million across the federal government in fiscal 2016 to prevent, detect and control illness and death related to infections caused by antibiotic-resistant bacteria.

12. President Obama proposed $100 million more in additional funding for domestic preparedness to “more effectively and efficiently respond to potential, future outbreaks here at home.” The funding would support emergency staffing, hospital and containment facilities, laboratory equipment and other means of fighting unexpected public health emergencies.

13. The budget would increase research and development funding by nearly 6 percent, providing the National Institutes of Health is seeking $31.1 billion, up from $30.31 billion in fiscal 2015, according to the Wall Street Journal. This would go toward the Brain Initiative, an effort to map the brain, and genomic research conducted by the NIH’s National Cancer Institute.

14. The budget also includes a proposal for an additional $80 million to the HHS Office of Inspector General to regulate fraud and abuse. Part of the money would be used to oversee the insurance markets created under the PPACA.

15. Finally, the Budget invests $73 million to manage and provide oversight to the HHS Cybersecurity Program, which is designed to reinforce and protect IT systems against the growing threats within the cyber community.